1.
Cancers (Basel)
; 14(9)2022 Apr 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35565179
RESUMO
Over the last decade, the treatment paradigm of metastatic renal cell carcinoma has rapidly evolved, with notable changes in the front-line setting. Combination therapies involving the use of either doublet therapy with immune checkpoint inhibitors or combination VEGFR-directed therapies with immune checkpoint inhibitors have significantly improved clinical outcomes, including prolonged overall survival and durable response to treatment. We aim to highlight the Food and Drug Administration-approved front-line therapy options, the navigation of treatment selection, and the future directions of metastatic renal cell carcinoma therapies.
2.
JCO Precis Oncol
; 5: 767-770, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34994610